Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018

Gómez-Peralta, Fernando; Escalada, Javier; Torre, Edelmiro Menéndez; Cases, Manel Mata; García, Juan Carlos Ferrer; Loiola, Patxi Ezkurra; Lachica, Luis Ávila; Pérez, José Antonio Fornos; Menéndez, Sara Artola; Guisasola, Fernando Álvarez; Echevarría, Itxaso Rica; Borrás, Juan Girbés

doi:10.1016/j.endinu.2018.08.004

Cited by 32 publications

(13 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly in most parts of the world, which is likely to increase the incidence of complications associated with the disease [1]. This situation calls for improved treatment of hyperglycaemia and other risk factors associated with T2DM in order to lower the risk of both micro-and macrovascular complications and their related economic costs, as proposed by all international and national consensus documents and guidelines [2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

“…Despite scientific evidence from a number of cardiovascular outcome trials (CVOTs) [7][8][9] and the guideline recommendations [2][3][4][5][6], adequate management of these patients remains beset with challenges. Several observational studies performed around the world report a gap between guideline recommendations and daily clinical practice [10][11][12][13][14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database

Mata-Cases

Franch-Nadal

Real

et al. 2021

Primary Care Diabetes

View full text Add to dashboard Cite

Aims: To describe the characteristics and antidiabetic treatment among type 2 diabetes patients according to the clinical conditions prioritized in the Spanish 2020 RedGDPS (Primary Care Diabetes Study Groups Network) therapeutic algorithm: obesity, older than 75 years, chronic kidney disease, cardiovascular disease, and heart failure. Methods: Retrospective, cross-sectional study. Clinical characteristics, the use of antidiabetic drugs and the KDIGO renal risk categories at 31.12.2016 were retrieved from the SIDIAP (Information System for Research in Primary Care) database (Catalonia, Spain). Results: From a total of 373,185 type 2 diabetes patients, 37% were older than 75 years, 45% obese, 33% had chronic kidney disease, 23.2% cardiovascular disease and 6.9% heart failure. Insulin was more frequently prescribed in chronic kidney disease, cardiovascular disease and heart failure whereas Sodium-Glucose cotransporter 2 inhibitors and Glucagon Like Peptide 1 receptor agonists were scarcely prescribed (2.6% and 1.4%, respectively). Among patients with severe renal failure, contraindicated drugs like metformin (16%) and sulfonylureas (6.1%) were still in use. The 2012 KDIGO renal risk categories distribution was: Low: 60.9%, Moderate: 21.6%, High: 9.8% and Very high: 7.7%. Conclusions: Almost 80% of our T2DM patients meet one of the five clinical conditions that should be considered for treatment individualization. Importantly, a relevant number of patients with severe renal failure were found to use contraindicated drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database

Mata-Cases

Franch-Nadal

Real

et al. 2021

Primary Care Diabetes

View full text Add to dashboard Cite

show abstract

“…These clinically challenging situations are based on the crossroads described in the American Diabetes Association algorithm for pharmacological treatment of T2DM 35. However, these situations and recommendations are similar to those found in other clinical guidelines for the treatment of T2DM 32,36. Adjustment of concomitant treatment, safety cautions, and efficacy expectancy are also detailed.…”

Section: Conclusion and Practical Positioning Of Semaglutide In Type mentioning

confidence: 92%

“…Information to patients about managing food intake and reducing fat content may reduce the incidence of nausea and vomiting 37. If gastrointestinal side effects are observed, dose titration should be considered, by maintaining or reducing the semaglutide dose to 0.5 or 0.25 mg 36…”

Section: Conclusion and Practical Positioning Of Semaglutide In Type mentioning

confidence: 99%

<p>Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy</p>

Gómez-Peralta¹,

Abreu²

2019

DDDT

Self Cite

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) has become one of the leading causes of morbidity and mortality in developed countries. Low efficacy, weight gain, and hypoglycemia are the main pitfalls of previous treatments for T2DM. New therapies have been designed with the aim of improving the results in efficacy and quality of life. Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RA) increase glucose-dependent insulin secretion, decrease gastric emptying, and reduce postprandial glucagon secretion. The last GLP-1 RA approved by the US Food and Drug Administration and European Medicines Agency was semaglutide. This review describes its pharmacology, core clinical data coming from the randomized controlled trials included in the development program, proven cardiovascular benefits, safety issues, and precautions for the use of semaglutide in special populations. Additionally, an overview of the positioning of semaglutide in T2DM therapy and practical issues regarding semaglutide initiation are offered.

show abstract

“…En el estudio de Fornos et al [24] el segundo porcentaje mayor corresponde con las sulfonilureas. Esto se corresponde con las guías de consenso para el tratamiento del paciente diabético tipo 2, en las cuales se recomienda como primera línea de tratamiento metformina y si los objetivos no son alcanzados en 3 meses, se pasaría a combinar con una sulfonilurea o un iDPP-4 u otros [25,26].…”

Section: Utilización De Medicamentosunclassified

Evaluación de la no adherencia al tratamiento hipoglucemiante en la farmacia comunitaria

Leites-Docío¹,

García-Rodríguez²,

Fernández-Cordeiro³

et al. 2019

View full text Add to dashboard Cite

Introducción: La adherencia al tratamiento en enfermedades crónicas como la diabetes mellitus (DM) es de vital importancia. El incumplimiento está directamente implicado en el aumento del número de medicamentos prescritos en enfermos crónicos y es una de las causas más importantes de fracaso de los tratamientos. Objetivos: Evaluar en la farmacia comunitaria la prevalencia de no adherencia al tratamiento en DM tipo 2 mediante la realización del cuestionario MMAS-8. Material y métodos: Estudio observacional transversal realizado en mayo y junio de 2018. Se seleccionaron pacientes mayores de 45 años, en tratamiento con hipoglucemiantes. Se midió la adherencia farmacoterapéutica mediante la administración del cuestionario (MMAS-8) según la puntuación obtenida en el test y la percepción que tienen sobre su tratamiento. Resultados: Participaron 64 pacientes, 29 (45,3%) mujeres y 35 (54,7) hombres. Las mujeres tenían 65,5 años de edad media (DE=15,3) y los hombres 65,6 años (DE=12,3). La puntuación media del test de MMAS-8 fue de 6,2±2,1, no encontrando diferencias significativas entre sexos. Se encontró que el número de pacientes con baja adherencia fueron 21 (32,8%), con media adherencia 19 (29,7%) y con alta adherencia 24 (37,5%). No se encontró relación entre el porcentaje de adherencia al tratamiento con el sexo, edad, nivel de estudios y condición laboral. La creencia de que el tratamiento mejora la enfermedad y que los medicamentos prescritos son los adecuados aumenta la adherencia. Conclusiones: El cuestionario MMAS-8 se ha mostrado como una herramienta rápida y sencilla para la evaluación de la adherencia del tratamiento en la farmacia comunitaria.

show abstract

Recomendaciones de la Sociedad Española de Diabetes (SED) para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2: Actualización 2018

Cited by 32 publications

References 57 publications

Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database

Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: Data from a Mediterranean population database

<p>Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy</p>

Evaluación de la no adherencia al tratamiento hipoglucemiante en la farmacia comunitaria

Contact Info

Product

Resources

About